<?xml version="1.0" encoding="UTF-8"?>
<clinical_study rank="596">
  <!-- This xml conforms to an XML Schema at:
    https://clinicaltrials.gov/ct2/html/images/info/public.xsd -->
  <required_header>
    <download_date>ClinicalTrials.gov processed this data on December 16, 2021</download_date>
    <link_text>Link to the current ClinicalTrials.gov record.</link_text>
    <url>https://clinicaltrials.gov/show/NCT05153395</url>
  </required_header>
  <id_info>
    <org_study_id>2057288</org_study_id>
    <nct_id>NCT05153395</nct_id>
  </id_info>
  <brief_title>Impact of Intranasal Insulin on Sympathetic Activity and Cerebral Vasodilation</brief_title>
  <official_title>Impact of Intranasal Insulin on Sympathetic Activity and Cerebral Vasodilation</official_title>
  <sponsors>
    <lead_sponsor>
      <agency>University of Missouri-Columbia</agency>
      <agency_class>Other</agency_class>
    </lead_sponsor>
  </sponsors>
  <source>University of Missouri-Columbia</source>
  <oversight_info>
    <has_dmc>No</has_dmc>
    <is_fda_regulated_drug>Yes</is_fda_regulated_drug>
    <is_fda_regulated_device>No</is_fda_regulated_device>
  </oversight_info>
  <brief_summary>
    <textblock>
      The purpose of this project is to examine the impact of increases in brain insulin on&#xD;
      sympathetic nervous system activity, as well as peripheral and cerebral blood flow in humans.&#xD;
    </textblock>
  </brief_summary>
  <overall_status>Recruiting</overall_status>
  <start_date type="Anticipated">December 2021</start_date>
  <completion_date type="Anticipated">January 2023</completion_date>
  <primary_completion_date type="Anticipated">January 2023</primary_completion_date>
  <phase>Early Phase 1</phase>
  <study_type>Interventional</study_type>
  <has_expanded_access>No</has_expanded_access>
  <study_design_info>
    <allocation>N/A</allocation>
    <intervention_model>Single Group Assignment</intervention_model>
    <primary_purpose>Basic Science</primary_purpose>
    <masking>None (Open Label)</masking>
  </study_design_info>
  <primary_outcome>
    <measure>Amount of muscle sympathetic nerve activity (MSNA)</measure>
    <time_frame>Change from baseline at minute 60</time_frame>
    <description>MSNA burst incidence (bursts/100 heart beats)</description>
  </primary_outcome>
  <primary_outcome>
    <measure>Amount of leg blood flow</measure>
    <time_frame>Change from baseline at minute 60</time_frame>
    <description>Measured with Doppler ultrasound (mL/min)</description>
  </primary_outcome>
  <secondary_outcome>
    <measure>Amount of cerebral blood flow</measure>
    <time_frame>Change from baseline at minute 60</time_frame>
    <description>Measured with trans-cranial Doppler ultrasound (cm/s)</description>
  </secondary_outcome>
  <number_of_arms>1</number_of_arms>
  <enrollment type="Anticipated">27</enrollment>
  <condition>Healthy</condition>
  <condition>Vasodilation</condition>
  <condition>Insulin Resistance</condition>
  <condition>Autonomic Dysfunction</condition>
  <arm_group>
    <arm_group_label>Insulin</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
    <description>Human insulin (160 IU) will be administered as a bolus using an intra-nasal device.</description>
  </arm_group>
  <intervention>
    <intervention_type>Other</intervention_type>
    <intervention_name>Carbon dioxide breathing</intervention_name>
    <description>Hypercapnic (5% carbon dioxide) air will be administered before and after intra-nasal insulin exposure.</description>
    <arm_group_label>Insulin</arm_group_label>
  </intervention>
  <intervention>
    <intervention_type>Other</intervention_type>
    <intervention_name>Neurovascular Coupling</intervention_name>
    <description>Participants will be asked to repeatedly open and close their eyes. With eyes open, participants will focus on a visual image. This will be done before and after intra-nasal insulin exposure.</description>
    <arm_group_label>Insulin</arm_group_label>
  </intervention>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>Human insulin</intervention_name>
    <description>Participants will be administered human insulin (160 IU) as a bolus using an intra-nasal device.</description>
    <arm_group_label>Insulin</arm_group_label>
  </intervention>
  <eligibility>
    <criteria>
      <textblock>
        Inclusion Criteria:&#xD;
&#xD;
          -  healthy adult men and women;&#xD;
&#xD;
          -  18-45 years of age;&#xD;
&#xD;
          -  BMI 18-30 kg/m2;&#xD;
&#xD;
          -  non-pregnant/non-breastfeeding;&#xD;
&#xD;
          -  non-nicotine users;&#xD;
&#xD;
        Exclusion Criteria:&#xD;
&#xD;
          -  taking any medications known to affect metabolic, respiratory, cardiovascular, and/or&#xD;
             autonomic&#xD;
&#xD;
        Self-reported history of:&#xD;
&#xD;
          -  hepatic, renal, pulmonary, cardiovascular, or neurological disease;&#xD;
&#xD;
          -  stroke or neurovascular disease;&#xD;
&#xD;
          -  bleeding/clotting disorders;&#xD;
&#xD;
          -  sleep apnea or other sleep disorders;&#xD;
&#xD;
          -  diabetes;&#xD;
&#xD;
          -  smoking;&#xD;
&#xD;
          -  history of alcoholism or substance abuse;&#xD;
&#xD;
          -  hypertension;&#xD;
&#xD;
          -  respiratory disease;&#xD;
&#xD;
          -  active cancer;&#xD;
&#xD;
          -  autoimmune disease.&#xD;
      </textblock>
    </criteria>
    <gender>All</gender>
    <minimum_age>18 Years</minimum_age>
    <maximum_age>45 Years</maximum_age>
    <healthy_volunteers>Accepts Healthy Volunteers</healthy_volunteers>
  </eligibility>
  <overall_official>
    <last_name>Jacqueline K Limberg, Ph.D.</last_name>
    <role>Principal Investigator</role>
    <affiliation>University of Missouri-Columbia</affiliation>
  </overall_official>
  <overall_contact>
    <last_name>Jennifer L Harper, B.S.</last_name>
    <phone>5738822544</phone>
    <email>harperjl@missouri.edu</email>
  </overall_contact>
  <location>
    <facility>
      <name>University of Missouri</name>
      <address>
        <city>Columbia</city>
        <state>Missouri</state>
        <zip>65211</zip>
        <country>United States</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Jennifer L Harper</last_name>
      <phone>573-882-2544</phone>
      <email>harperjl@missouri.edu</email>
    </contact>
  </location>
  <location_countries>
    <country>United States</country>
  </location_countries>
  <verification_date>December 2021</verification_date>
  <study_first_submitted>November 18, 2021</study_first_submitted>
  <study_first_submitted_qc>December 8, 2021</study_first_submitted_qc>
  <study_first_posted type="Actual">December 10, 2021</study_first_posted>
  <last_update_submitted>December 8, 2021</last_update_submitted>
  <last_update_submitted_qc>December 8, 2021</last_update_submitted_qc>
  <last_update_posted type="Actual">December 10, 2021</last_update_posted>
  <responsible_party>
    <responsible_party_type>Principal Investigator</responsible_party_type>
    <investigator_affiliation>University of Missouri-Columbia</investigator_affiliation>
    <investigator_full_name>Jacqueline K Limberg, PhD</investigator_full_name>
    <investigator_title>Assistant Professor</investigator_title>
  </responsible_party>
  <condition_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Autonomic Nervous System Diseases</mesh_term>
    <mesh_term>Primary Dysautonomias</mesh_term>
    <mesh_term>Insulin Resistance</mesh_term>
  </condition_browse>
  <intervention_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Insulin</mesh_term>
    <mesh_term>Insulin, Globin Zinc</mesh_term>
  </intervention_browse>
  <patient_data>
    <sharing_ipd>Undecided</sharing_ipd>
  </patient_data>
  <!-- Results have not yet been posted for this study                                          -->
</clinical_study>

